Fresenius Kabi AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
65
About the Report
About the Report
Summary
Fresenius Kabi AG (Fresenius Kabi), a wholly owned subsidiary of Fresenius SE & Co KGaA, develops, manufactures and markets pharmaceuticals products and medical devices. The company's product portfolio includes intravenously administered drugs, infusion therapy products, medical devices and clinical nutrition products. It covers therapeutic areas such as blood volume substitution, fluid management, anesthesia, critical illness, liver insufficiency, renal insufficiency, maldigestion or malabsorption, diabetes mellitus and pediatrics. Its products and services are used for the treatment of critically and chronically ill patients. Fresenius Kabi conducts sales and marketing operations through direct offices worldwide. The company has its facilities in Europe, North America, Latin America, Asia Pacific and Africa. Fresenius Kabi is headquartered in Bad Homburg, Germany.
Fresenius Kabi AG-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fresenius Kabi AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Fresenius Kabi AG, Medical Devices Deals, 2012 to YTD 2018 10
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 12
Fresenius Kabi India To Acquire Manufacturing Unit Of Goa Formulations For USD 37 Million 13
APP Pharma Acquires Three Critical Care Products From Nexus Pharma 14
Partnerships 15
Otsuka Pharma Factory Enters Into Distribution Agreement With Fresenius Kabi Japan For HES Products 15
Provepharm Enters Into Distribution Agreement With Fresenius Kabi Pharma 16
Licensing Agreements 17
Medicines Company Enters Into Licensing Agreement With APP For Acute Care Generic Products 17
Caplin Point Laboratories Enters into Licensing and Distribution Agreement with Fresenius Kabi USA 18
InnoPharma Enters Into Licensing Agreement With Fresenius Kabi For Acetylcysteine Solution 19
Asset Transactions 20
Xellia Acquires Lyophilized Manufacturing Facility from Fresenius Kabi 20
Acquisition 21
NewCo Pharma Acquires CFL from Fresenius Kabi 21
Fresenius Kabi Acquires Novafarma Industria Farmaceutica 22
Fresenius Kabi Acquires 51% Stake in Ethica Industri Farmasi From Soho Global Halthcare 23
Fresenius Kabi (Singapore) To Delist Its Indian Arm 24
Linde To Acquire Calea France From Fresenius Kabi 25
Fresenius Kabi Completes Acquisition Of Fenwal From TPG Capital And Maverick Capital For USD 1.1 Billion 26
Fresenius Kabi Plans To Sell 15% Stake In Fresenius Kabi Oncology 28
Fresenius Kabi AG-Key Competitors 29
Fresenius Kabi AG-Key Employees 30
Fresenius Kabi AG-Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Joint Venture 36
Recent Developments 37
Strategy And Business Planning 37
Oct 12, 2018: Fresenius Kabi opens compounding center in Canada 37
Jun 22, 2018: Fresenius Kabi UK expands operations in Runcorn, England 38
Nov 24, 2017: Fresenius Kabi opens production facility in Indonesia 39
Jul 06, 2017: Fresenius Kabi expands production site in Portugal 40
Financial Announcements 41
Oct 30, 2018: Fresenius in Q3/18 with continued strong Group earnings growth in constant currency 41
Feb 26, 2018: Fresenius remains on growth course after 14 straight record years 47
Nov 02, 2017: Fresenius reports another strong quarter and confirms guidance 54
Corporate Communications 56
Oct 10, 2017: Fresenius Kabi's Generic Drugs Business Unit Head elected as president of Medicines for Europe 56
Legal and Regulatory 57
Oct 01, 2018: Akorn comments on Delaware Chancery Court Ruling 57
May 28, 2018: New EU Commission's initiative SPC manufacturing waiver 58
Feb 26, 2018: Akorn Issues Statement on Investigation 59
Jan 29, 2018: HES solutions should remain on the market 60
Jan 03, 2018: USFDA issues warning letter to Fresenius Kabi for Baddi plant 61
Government and Public Interest 62
Nov 30, 2017: Statement by FDA Commissioner Scott Gottlieb, M.D., updating on Puerto Rico related medical product shortages 62
Other Significant Developments 63
Sep 08, 2017: Fresenius Kabi marks 20-year anniversary of Friedberg production site - Logistics center expansion planned 63
Mar 10, 2017: Fresenius Kabi builds new warehouse at Blonie production site 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65
List of Figure
List of Figures
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Fresenius Kabi AG, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fresenius Kabi AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fresenius Kabi AG, Deals By Therapy Area, 2012 to YTD 2018 9
Fresenius Kabi AG, Medical Devices Deals, 2012 to YTD 2018 10
Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 12
Fresenius Kabi India To Acquire Manufacturing Unit Of Goa Formulations For USD 37 Million 13
APP Pharma Acquires Three Critical Care Products From Nexus Pharma 14
Otsuka Pharma Factory Enters Into Distribution Agreement With Fresenius Kabi Japan For HES Products 15
Provepharm Enters Into Distribution Agreement With Fresenius Kabi Pharma 16
Medicines Company Enters Into Licensing Agreement With APP For Acute Care Generic Products 17
Caplin Point Laboratories Enters into Licensing and Distribution Agreement with Fresenius Kabi USA 18
InnoPharma Enters Into Licensing Agreement With Fresenius Kabi For Acetylcysteine Solution 19
Xellia Acquires Lyophilized Manufacturing Facility from Fresenius Kabi 20
NewCo Pharma Acquires CFL from Fresenius Kabi 21
Fresenius Kabi Acquires Novafarma Industria Farmaceutica 22
Fresenius Kabi Acquires 51% Stake in Ethica Industri Farmasi From Soho Global Halthcare 23
Fresenius Kabi (Singapore) To Delist Its Indian Arm 24
Linde To Acquire Calea France From Fresenius Kabi 25
Fresenius Kabi Completes Acquisition Of Fenwal From TPG Capital And Maverick Capital For USD 1.1 Billion 26
Fresenius Kabi Plans To Sell 15% Stake In Fresenius Kabi Oncology 28
Fresenius Kabi AG, Key Competitors 29
Fresenius Kabi AG, Key Employees 30
Fresenius Kabi AG, Other Locations 31
Fresenius Kabi AG, Subsidiaries 33
Fresenius Kabi AG, Joint Venture 36
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.